H-ECCO
19December2022

My experience as H-ECCO Committee Chair

Gert de Hertogh, H-ECCO Chair

Gert de Hertogh
© ECCO

The 15th Congress of ECCO was held in Vienna, Austria between February 12 and 15, 2020. During this meeting, it was decided that I would take over from Roger Feakins as second Chair of the H(istology)-ECCO Committee. The committee was at that time one of the most recently established. Its primary aim is to expand the knowledge of IBD histopathology by organising a yearly masterclass. However, the framework of ECCO also offers many other opportunities to support clinical decision-making, by linking with the other committees and by participation in the composition of ECCO Practice Guidelines, Position Statements and Topical Reviews.

Posted in ECCO News, Committee News, Volume 17, Issue 4, H-ECCO

13October2022

New Developments to Standardise the Assessment of Mucosal Histology in Crohn’s Disease

Gert de Hertogh, H-ECCO Chair

Gert de Hertogh
© ECCO

The past 6 months of 2022 have seen the publication of two important papers, one by F. Magro et al. (“The ECCO position on harmonisation of Crohn’s disease mucosal histopathology” [1]) and the other by I.O. Gordon et al. (“International consensus to standardise histopathological scoring for small bowel strictures in Crohn’s disease” [2]).

Posted in ECCO News, Committee News, Volume 17, Issue 3, H-ECCO

15June2022

New H-ECCO Member

Gert de Hertogh, H-ECCO Chair

Gert de Hertogh
© ECCO

The H-ECCO Committee is saying goodbye to Monika Tripathi and would like to thank her for all her work on behalf of the Committee in recent years.

At the same time, as chairman of the Committee, I am very happy to welcome our new member, Aart Mookhoek. Aart currently works as a pathologist at the Institute of Pathology, University of Bern, Switzerland. He is, however, Dutch originally, and developed his passion for gastrointestinal pathology during a residency and subsequent fellowship at the University of Amsterdam, the Netherlands. Aart and I trained together on histological scoring systems for disease activity in Ulcerative Colitis and Crohn’s Disease, and we participated in a research project on this topic.

Posted in ECCO News, Committee News, Volume 17, Issue 2, H-ECCO

28April2022

Report on the 7th H-ECCO IBD Masterclass at ECCO’22

Gert De Hertogh, H-ECCO Chair

Gert De Hertogh
© ECCO

Contrary to everyone’s ardent expectations and hopes, this year’s ECCO Congress was once again held virtually. While the experiences from 2021 had taught the H-ECCO Committee how to prepare for this and what to expect, we were so happy to be supported again by an excellent ECCO Office team.

Posted in ECCO News, Committee News, ECCO'22, Volume 17, Issue 1, H-ECCO

16December2021

Editorial on ECCO Topical Review on Clinicopathological Spectrum & Differential Diagnosis of IBD

Ann Driessen, H-ECCO Member

Ann Driessen
© ECCO

Inflammatory Bowel Disease is a longstanding recurrent inflammatory disorder that is most prevalent in Western countries but is increasing in Asiatic countries. The worldwide increase in the incidence of IBD, comprising Crohn’s Disease, Ulcerative Colitis and IBD unclassified, is having a significant impact on health care systems. Achievement of an optimal quality of care of IBD requires a multidisciplinary approach by different clinical disciplines, including pathology. Histopathology plays an essential role in the diagnosis and management of IBD. The pathologist excludes or confirms and subtypes IBD, assesses its activity and response to treatment and diagnoses preneoplastic lesions on endoscopic biopsies. Suboptimal sampling during endoscopy or insufficient clinical information, however, hampers the pathologist in making a diagnosis [1]. The main histological features of IBD are disturbance of the architecture and basal plasmacytosis, though a wide variety of disorders resemble IBD not only clinically and endoscopically but also histologically. Distinction between IBD and these mimics is essential as misdiagnosis results in delayed and incorrect management. Their differentiation is, however, not always straightforward and, in addition to a standard clinical examination, requires serology, imaging, endoscopy, histology and other investigations [2].

Posted in ECCO News, Committee News, Volume 16, Issue 4, H-ECCO

17September2021

Report on the 6th H-ECCO IBD Masterclass at ECCO’21

Gert De Hertogh, H-ECCO Chair

Gert De Hertogh
© ECCO

The past 2 years, 2020 and 2021, have been challenging for everybody, but with the help of the ever-enthusiastic ECCO Organisation and their co-workers, the H-ECCO Committee was able to organise a well-attended masterclass at the recent virtual congress in July.

We divided the masterclass into four sessions: Basics of IBD, Scoring Schemes and Standards, Neoplasia and New Concepts in IBD.

Posted in ECCO News, Committee News, ECCO'21, Volume 16, Issue 3, H-ECCO

29April2021

Histopathological diagnosis of paediatric-onset IBD

Pamela Baldin, H-ECCO Member

Pamela Baldin
© ECCO

Paediatric-onset Inflammatory Bowel Diseases (IBDs) represent about 25%–30% of all IBDs. As in adult patients, cases are classified as Ulcerative Colitis (UC) or Crohn’s Disease (CD). In addition, a third diagnostic category, unclassified-IBD (U-IBD), can be used when a definite differential diagnosis between UC and CD is not possible.

Paediatric-onset IBDs, by definition, are those IBDs which are diagnosed in children and adolescents under the age of 17 years. They are further categorised as very early onset IBD (VEO-IBD) when the disease is diagnosed before 6 years of age, infantile IBD when the diagnosis is made before 2 years of age and neonatal-onset IBD when the patient is 28 days old or less. 

Posted in ECCO News, Committee News, Volume 16, Issue 2, H-ECCO

15December2020

How to get the best out of your pathologist

Francesca Rosini, H-ECCO Member

Francesca Rosini 
© ECCO

The histological diagnosis of Inflammatory Bowel Disease (IBD) is not an easy task for a pathologist. In the modern era, personal pathology experience alone is insufficient to make a diagnosis of IBD. The information that a pathologist must know in order to evaluate IBD samples appropriately and to make a diagnosis is diverse, and for the most part should be provided by the gastroenterologists, surgeons or clinicians responsible for the care of patients. Even the most experienced pathologist cannot report a case without knowing the clinical background of the patient. Obviously, this should be the standard for all samples, not only for IBD.

Posted in ECCO News, Committee News, H-ECCO, Volume 15, Issue 4

30September2020

Animal Models: The View of the Pathologist

Ann Driessen and Pamela Baldin, H-ECCO Members


Ann Driessen
© ECCO

Pamela Baldin
© ECCO

The animal model is a useful tool to unravel different pathogenetic mechanisms, to detect biomarkers for monitoring and to test the efficacy and safety of drugs in the preclinical phase. In Inflammatory Bowel Disease (IBD) research, the mouse is the most widely used animal model. Animal models are classified into four categories, namely chemical models, cell transfer models, genetically engineered models, and congenic models. Based on the mechanism of the animal model, different aspects of the pathogenesis of intestinal inflammation in IBD are examined, such as epithelial integrity and wound healing, and innate and adaptive immunity [1].

Posted in ECCO News, Committee News, H-ECCO, Volume 15, Issue 3

30June2020

New members of the H-ECCO Committee

Gert De Hertogh, H-ECCO Chair


Gert De Hertogh 
© ECCO

As the new chair of the H-ECCO Committee, it is my pleasure to introduce our two newly elected members for 2020, Ann Driessen and Pamela Baldin, who are both Belgian pathologists. Thus, the current members of the H-ECCO Committee are: Monika Tripathi (Addenbrooke’s Hospital, Cambridge, UK), Francesca Rosini (Imperial College Healthcare NHS Trust, London, UK), Ann Driessen, Pamela Baldin, and myself, Gert De Hertogh (University Hospitals KULeuven, Belgium).

Posted in ECCO News, Committee News, H-ECCO, Volume 15, Issue 2